PTO/SB/30 (09-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
DEPaperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Request For Continued Examination (RCE) **Transmittal**

Address to: MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Application Number	09/844,864	
Filing Date	April 27, 2001	
First Named Inventor	Martin M. Matzuk	
Art Unit	1637	_
Examiner Name	C. B. Wilder	_
Attorney Docket No.	HO-P01925US2	

(Staci Harris)

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June

-,,,,			
1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).			
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.			
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on			
ii. Other			
b. x Enclosed			
i. X Amendment/Reply iii. Information Disclosure Statement (IDS)			
iiAffidavit(s)/Declaration(s) ivOth	er		
2. Miscellaneous			
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)			
b Other			
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.			
a. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 06-2375			
i. X RCE fee required under 37 CFR 1.17(e)			
ii. X Extension of time fee (37 CFR 1.136 and 1.17) -the difference between 2 month and 3 month fee is enclosed			
lii.    Other			
b enclosed			
c. Payment by credit card (Form PTO-2038 enclosed)			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Name (Print/Type) Melissa W. Acosta Reg	sistration No. (Attorney/Agent) 45,872		
Signature //	Date February 25, 2004		

**Request for Continued Examination Transmittal** 

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER509326895US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 25, 2004

Signature:

02/27/2004 JADDO1

00000129 062375 09844864 FEB 2 5 2004 No.

| Gereby certify that this correspond of the correspond of the correspond of the corresponding o

I bereby certify that this correspondence is being deposited with the U.S. Rostal Service as Express Mail, Airbill No. ER509326895US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 25, 2004

Signature: Staw Harris

Docket No.: HO-P01925US2

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Martin M. Matzuk, et al.

Application No.: 09/844,864

Art Unit: 1637

Filed: April 27, 2001

Examiner: Cynthia B. Wilder

For: OVARY-SPECIFIC GENES AND PROTEINS

## RCE AMENDMENT (37 C.F.R. 1.114)

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## **INTRODUCTORY COMMENTS**

In response to the Office Action dated August 26, 2003, the Advisory Action dated November 14, 2003 and the Advisory Action of February 9, 2004, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 3 of this paper.